Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources, which are used in cosmeceutical products, such as oat beta glucan and avenanthramides, and is being developed as potential nutraceuticals and/or pharmaceuticals. Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-1.


TSX:AEZS - Post by User

Bullboard Posts
Comment by pp19888on Nov 22, 2015 12:35pm
77 Views
Post# 24313777

RE:RE:RE:RE:Maybe Martin Shkreli can help AZ...

RE:RE:RE:RE:Maybe Martin Shkreli can help AZ...That's what management did last time brutal financing, right? Why not again? Also, 800000 non participating warrants at 0.054 converts at around 30M before reverse split, so now after reverse split we are looking for 300000 shares. Now, if stock could go below 3.00 we are looking around 600000 more shares to add into current float 10% of outstanding shares, and If it continue to slides keep adding more shares into float. Its your take, if you think this is the right entry point, I would rather wait to see cleaning up all outstanding warrants. Also, If I would have millions why should I buy in open market if I knew that managament is in need of money. I would rather approch management directly for investment is that simple. Remember no value to pharma stock if no FDA approval!!!
Bullboard Posts